Alphamab Oncology 2021 SR
The report highlights Alphamab Oncology's 2021 ESG performance, focusing on the commercialization of ENWEIDA, the world's first subcutaneously injected PD-L1 inhibitor. The company expanded its R&D team by 25% and increased R&D investment by 45%, while achieving significant clinical progress for candidates like KN046 and KN026. Environmentally, the company reduced its total energy consumption intensity by 47.23% and GHG emission intensity by 48.62% compared to 2020. Socially, it maintained a 100% employee training rate and reported zero work-related fatalities.
Company: Alphamab Oncology
Sector: Manufacturing
Country: China
Year: 2021
Type: SR
Pages: 54
Back to company
Alphamab Oncology
ESG Report
The report highlights Alphamab Oncology's 2021 ESG performance, focusing on the commercialization of ENWEIDA, the world's first subcutaneously injected PD-L1 inhibitor. The company expanded its R&D team by 25% and increased R&D investment by 45%, while achieving significant clinical progress for candidates like KN046 and KN026. Environmentally, the company reduced its total energy consumption intensity by 47.23% and GHG emission intensity by 48.62% compared to 2020. Socially, it maintained a 100% employee training rate and reported zero work-related fatalities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees